



Financial Tear Sheet

Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.


Uroplasty products are typically used when a patient's treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

Primary IR Contact

Doug Sherk
 EVC Group
 Phone: 415.896.6818
 Fax: 415.896.6821
 E-mail: dsherk@evcgroup.com

Stock Performance

UPI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	D
Price	\$ 1.61
Change (%)	▲ 0.03 (1.90%)
Volume	25,521
52 Week Low	\$1.42
Market Cap	\$0
Rolling EPS	-0.16
PE Ratio	N/A
Shares Outstanding	0
Data as of 05/01/15 4:00 p.m. ET	



Recent Headlines & Events

- 03/31/15
Uroplasty and Vision-Sciences Complete Merger
- 03/30/15
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
- 03/03/15
Uroplasty to Host Investor Meeting at Corporate Headquarters

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation:

Sell Strong Buy

EPS Trend				
		Current	30 Days Ago	90 Days Ago
QTR				
QTR				
QTR				
QTR				
FY				
FY				

SEC Filings

Year Filter	
<input type="text" value="All Years"/>	
Filing Date	Form
07/07/15	SC 13G/A
07/07/15	SC 13G/A
05/13/15	4/A
04/17/15	15-12B

Corporate Governance

Rob Kill	President and CEO
Brett Reynolds	Chief Financial Officer
Darin Hammers	Senior Vice President of Global Sales and Marketing
Marc M. Herregraven	Vice President of Manufacturing
Dan Merz	Vice President of Healthcare Affairs
Dave Perry	Vice President of Marketing
Dr. Suranjan Roychowdhury	Vice President of Research & Development and Clinical Affairs

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

* Insider values reflect direct beneficial ownership.

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed